|
1）Luznik L, Jalla S, Engstrom LW, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001; 98: 3456-64
|
|
|
|
2）Jones RJ, Barber JP, Vala MS, et al. Assessment of aldehyde dehydrogenase in viable cells. Blood. 1995; 85: 2742-6
|
|
|
|
|
|
3）Luznik L, OʼDonnell PV, Symons HJ, et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2008; 14: 641-50
|
|
|
|
|
|
4）Storb R, Graham TC, Shiurba R, et al. Treatment of canine graft-versus-host disease with methotrexate and cyclo-phosphamide following bone marrow transplantation from histoincompatible donors. Transplantation. 1970; 10: 165-72. No abstract available
|
|
|
|
|
|
5）Santos GW, Tutschka pJ, Brookmeyer R, et al. Cyclosporine plus methylprednisone versus cyclophosphamide plus methylprednisone as prophylaxis for graft-versus-host disease: A randomized double-blinded study in patients undergoing allogeneic marrow transplantation. Clin Transplantation. 1987; 1: 21-8
|
|
|
|
|
|
6）OʼDonnell PV, Luznik L, Jones RJ, et al. Nonmyeloablative bone marrow transplantation from partially HLA-mismatched related donors using posttransplantation cyclophosphamide. Biol Blood Marrow Transplant. 2002; 8: 377-86
|
|
|
|
|
|
7）Kanakry CG, Ganguly S, Zahurak M, et al. Aldehyde dehydrogenase expression drives human regulatory T cell resistance to posttransplantation cyclophosphamide. Sci Transl Med. 2013; 5: 211ra157
|
|
|
|
|
|
8）Solomon SR, Sizemore CA, Sanacore M, et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant. 2012; 18: 1859-66
|
|
|
|
|
|
9）Raiola AM, Dominietto A, Ghiso A, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013; 19: 117-22
|
|
|
|
|
|
10）Brunstein CG, Fuchs EJ, Carter SL, et al. Alternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts. Blood and Marrow Transplant Clinical Trials Network. Blood. 2011; 118: 282-8
|
|
|
|
|
|
11）Bashey A, Zhang X, Sizemore CA, et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol. 2013; 31: 1310-6
|
|
|
|
|
|
12）Raiola AM, Dominietto A, Di Grazia C, et al. Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts. Biol Blood Marrow Transplant. 2014; 20: 1573-9
|
|
|
|
|
|
13）Symons HJ, Leffell MS, Rossiter ND, et al. Improved survival with inhibitory killer immunoglobulin receptor (KIR) gene mismatches and KIR haplotype B donors after nonmyeloablative, HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2010; 16: 533-42
|
|
|
|
|
|
14）Munchel AT, Kasamon YL, Fuchs EJ. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol. 2011; 24: 359-68
|
|
|
|
|
|
15）Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014; 20: 314-8
|
|
|
|
|
|
16）Luznik L, Fuchs EJ. High-dose, post-transplantation cyclophosphamide to promote graft-host tolerance after allogeneic hematopoietic stem cell transplantation. Immunol Res. 2010; 47: 65-77
|
|
|
|
|